trending Market Intelligence /marketintelligence/en/news-insights/trending/nRB5MuiiuWDwiMsL_dFS1w2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Adamis answers US FDA's concerns over opioid overdose therapy Zimhi

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Adamis answers US FDA's concerns over opioid overdose therapy Zimhi

Adamis Pharmaceuticals Corp. has submitted its answers to the U.S. Food and Drug Administration's concerns after the regulator rejected the company's opioid overdose injection Zimhi.

The FDA rejected the company's therapy in November, raising questions about the chemistry, manufacturing and controls for Zimhi.

Adamis has also requested to meet the FDA in a type A meeting, a label reserved for meetings that are immediately necessary for halted drug development to continue.

The company will provide the next update to its drug application for Zimhi, a high dose of the drug blocking therapy naloxone, after the company's meeting with the FDA.